NCT00051844已完成2 期
A Double Blind- Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 179
- 试验地点
- 52
- 主要终点
- The primary objective was to determine whether the addition of capravirine to a regimen of VIRACEPT and 2 new nucleoside reverse transcriptase inhibitors would provide a higher virologic response rate over 48 weeks
研究概览
简要总结
This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female at least 18 years old
- •HIV RNA level >1000 copies/mL at screening
- •CD4 >50 cells/uL at screening
- •Patient is currently taking a regimen that includes an NNRTI plus 2 NRTIs for at least 28 days and is currently failing this regimen
- •Patient has adequate hematology tests (absolute neutrophil count >1000/uL, Platelets>75,000uL, hemoglobin 9g/L)
- •Patient has adequate renal function (serum creatinine of <1.5 upper limit of normal)
- •Patient has adequate liver function (AST, ALT, and bilirubin < 2.5 upper limit of normal)
排除标准
- •Previous use of protease inhibitors (except if patient has short duration of PI and was switched for tolerability reasons when viral load was <50 copies) This exception does not include Viracept
- •Women who are pregnant or lactating
结局指标
主要结局
The primary objective was to determine whether the addition of capravirine to a regimen of VIRACEPT and 2 new nucleoside reverse transcriptase inhibitors would provide a higher virologic response rate over 48 weeks
when compared to a 3-drug regimen without capravirine in patients who had experienced virologic failure while on a nonnucleoside reverse transcriptase inhibitor regimen.
次要结局
- The safety and tolerability of 2 doses of capravirine.
- The difference between 2 doses of capravirine in terms of tolerability, efficacy, and pharmacokinetics
- The relationship of HIV resistance (genotype and phenotype) to virologic response.
- The immunologic response as determined by CD4 and CD8 absolute lymphocyte counts
- The population pharmacokinetics of capravirine and VIRACEPT
- The pharmacokinetics of potential drug-drug interactions.
研究者
研究点 (52)
Loading locations...
相似试验
已完成
1 期
A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African AdultsHIV InfectionsNCT00549523University of Missouri-Columbia133
Unknown
1 期
Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy VolunteersHIV InfectionsNCT03730311Viriom24
已完成
1 期
Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected AdultsHIV-1 InfectionNCT03844386University of North Carolina, Chapel Hill26
已完成
2 期
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral RegimensHIV InfectionsNCT00052117Pfizer300
已完成
2 期
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAARTHIV-1 InfectionNCT01403051Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections167